Reverse Payment Patent Settlements: The Supreme Court Has Spoken

Reverse Payment Patent Settlements: The Supreme Court Has Spoken

Speaking Engagement
On June 17, 2013, the Supreme Court issued its long-awaited decision in FTC v. Actavis. After years of litigation in the lower courts, this is the first time the Court weighed in on the antitrust treatment of “reverse payment” (sometimes also known as “pay-for-delay”) patent settlements between branded and generic pharmaceutical manufacturers. This panel discussion, sponsored by the ABA Section of Antitrust Law’s Health Care and Pharmaceuticals Committee, provides a first analysis of the Court’s landmark decision.

WilmerHale Partner Hartmut Schneider moderated this event.

Read More About the Event



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.